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lar weight (MMW) adiponectin, but not LMW adiponectin, 
than middle-aged individuals with T2D. Female, but not 
male, octogenarians revealed significantly lower total adipo-
nectin than normoglycemic octogenarians. Compared with 
normoglycemic octogenarians, male and female octogenar-
ians with T2D were characterized by significantly lower LMW 
adiponectin. In male and female octogenarians, total adipo-
nectin and all multimer isoforms were directly correlated 
with HDL cholesterol. LMW adiponectin in octogenarians of 
both sexes was inversely correlated with glucose level at 
2-hour oral glucose tolerance test.  Conclusions: Serum lev-
els of total adiponectin as well as its HMW and MMW iso-
forms were significantly higher in octogenarians with nor-
moglycemia or T2D than in corresponding middle-aged 
control groups. In male and female octogenarians without 
metabolic syndrome, T2D was associated with lower LMW 
adiponectin, while the HMW and MMW isoforms were not 
statistically different.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 With aging, there is an increased prevalence of insulin 
resistance and type 2 diabetes (T2D) resulting in a high 
risk for cardiovascular disease. However, humans over 80 
years old are often spared age-related cardiovascular dis-
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 Abstract 
 Background: Adiponectin circulates in the blood in three 
different multimer isoforms, of which the high molecular 
weight form (HMW) is presumed to mediate insulin sensitiv-
ity. We examined whether adiponectin oligomer distribu-
tion is associated with aging and type 2 diabetes (T2D) in 
octogenarians without characteristic features of metabolic 
syndrome.  Methods: The study included 154 octogenarians 
(58 men, 96 women), 24 normoglycemic middle-aged con-
trols (11 men, 13 women; mean age 44 years), and 33 middle-
aged individuals (14 men, 19 women; mean age 55 years) 
with T2D. Based on oral glucose tolerance test 62 octogenar-
ians had normal, 63 impaired glucose tolerance, and 29 oc-
togenarians had newly detected T2D. Serum adiponectin 
multimer isoforms were measured after overnight fast by 
enzyme-linked immunosorbent assays.  Results:  Compared 
to the normoglycemic middle-aged control group, male nor-
moglycemic octogenarians revealed significantly higher to-
tal adiponectin and all adiponectin isoforms. The same was 
true for females with the exception of low molecular weight 
(LMW) adiponectin, which was not statistically higher in oc-
togenarians. Male and female octogenarians with T2D had 
significantly higher levels of total, HMW, and middle molecu-
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eases, probably, in part, due to the preservation of their 
insulin sensitivity  [1] . There is growing evidence that the 
adipocyte-derived hormone adiponectin plays a protec-
tive role against insulin resistance  [2] , atherosclerosis  [3] , 
and aging  [4] . Adiponectin exerts its favorable effects on 
insulin sensitivity in vivo through an activation of 5  -
AMP-activated protein kinase (AMPK) in skeletal mus-
cle and liver  [5] . Activated AMPK increases fatty acid ox-
idation and glucose uptake in myocytes and decreases 
hepatic glucose production by reduced expression of mol-
ecules involved in gluconeogenesis in the liver  [5, 6] . 
 Adiponectin circulates in the blood in three different 
isoforms: low molecular weight (LMW) trimers (about 67 
kDa), middle molecular weight (MMW) hexamers (about 
136 kDa), and high molecular weight (HMW) multimers 
( 1 300 kDa)  [7–9] . Furthermore, globular adiponectin, a 
proteolytic cleavage product of adiponectin, is also pres-
ent in human plasma  [6] . Concentrations of HMW and 
MMW isoforms are significantly higher in women than 
in men  [10] , while no gender differences have been found 
for the LMW form  [11] . Similarly to total adiponectin, 
HMW adiponectin has been shown to correlate directly 
with HDL cholesterol and inversely with triglycerides, in-
sulin sensitivity, and inflammatory markers in T2D pa-
tients  [10] .
 Experimental and clinical data suggest that the oligo-
meric complex distribution of adiponectin is essential for 
its anti-diabetic and anti-atherogenic activity  [12, 13] , 
and changes in the relative abundance of each oligomeric 
isoform in plasma may determine adiponectin activity. In 
subjects with metabolic syndrome, plasma levels of HMW 
adiponectin and the HMW to total adiponectin ratio 
were more effective in the prediction of insulin resistance 
than total adiponectin level  [14] . The improvement of in-
sulin sensitivity by thiazolidinedione treatment was rath-
er associated with increased levels of serum HMW than 
total adiponectin  [7] . In contrast to HMW adiponectin, 
the role of LMW adiponectin in the pathogenesis of T2D 
and insulin resistance is less defined. On the one hand, 
plasma LMW adiponectin was lower in obese individuals 
and in patients with T2D  [15] . It was negatively correlated 
with waist circumference, body mass index (BMI) and 
waist-to-hip ratio (WHR)  [15] . On the other hand, LMW 
adiponectin, like HMW and MMW adiponectin, was di-
rectly correlated with HDL cholesterol  [16] . Based on this 
strong correlation, HDL cholesterol may account for 
some of the anti-diabetic and anti-atherogenic actions 
that have been attributed to adiponectin so far. However, 
there are several studies reporting biological actions of 
LMW adiponectin exceeding presumed effects of HDL 
cholesterol. Thus, LMW adiponectin specifically reduced 
monocytic IL-6 secretion in vitro  [15, 17] . This in turn 
might attenuate obesity-induced systemic inflammation 
in vivo.
 Apart from insulin sensitization of peripheral tissues, 
adiponectin has been shown to exert significant effects 
on energy homeostasis via central mechanisms. Treat-
ment of mice with intracerebroventricular injections of 
adiponectin resulted in decreased body weight and fat 
content mediated by hypothalamic AdipoR1 receptors 
 [18, 19] . The total adiponectin concentration in human 
cerebrospinal fluid approximates 0.1% of the plasma con-
centration  [20, 21] , but LMW adiponectin is the predom-
inant adiponectin isoform in cerebrospinal fluid  [20, 21] . 
Thus, LMW adiponectin through its central action may 
exert a much higher biological significance than is cur-
rently acknowledged. 
 The present study aimed to characterize the metabol-
ic state of a group of octogenarians by an oral glucose 
tolerance test (OGTT) and to elucidate the interrelated 
effects of aging, sex, and insulin resistance on plasma ad-
iponectin isoform distribution. 
 Research Design and Methods 
 Study Population 
 One hundred and fifty-four octogenarians (58 men, age 82.9 
 8 3.8 years; 96 women, age 83.2  8 4.3 years) without a personal 
or family history of T2D among first-degree relatives were en-
rolled at the Spreewaldklinik Rehabilitation Hospital, Burg 
 (Spreewald), Germany. The study was performed in accordance 
with the Declaration of Helsinki and approved by the local Ethics 
Committee. Written informed consent was obtained from every 
subject. Patients with known T2D, plasma LDL cholesterol  6 4.5 
m M , triglycerides  6 2.6 m M , heart failure and severe chronic dis-
eases, as well as postoperative status were excluded from the 
study.
 For comparison, 24 normoglycemic middle-aged control indi-
viduals (aged 44  8 7 years, 11 men, 13 women) and 33 middle-
aged individuals with T2D (aged 55  8 8 years, 14 men, 19 women) 
were recruited. 
 All individuals underwent a standardized clinical examina-
tion, and current medication was recorded. Blood samples were 
taken after 12-hour overnight fast for routine laboratory analys - 
es. Subsequently, a standard 75 g OGTT was performed. During 
OGTT, plasma levels of glucose, insulin, C-peptide, proinsulin 
and free fatty acids were determined at 0, 30, 60, 90, and 120 min. 
Serum samples for adiponectin and hormone measurements were 
prepared immediately, shock frozen in liquid nitrogen and stored 
at –80   °   C until analysis. Impaired glucose tolerance (IGT) and 
T2D were diagnosed according to the ADA and World Health 
Organization criteria  [22] . Normal glucose tolerance (NGT) was 
diagnosed in 62 (24 men, 38 women), IGT in 63 (24 men, 39 wom-
en) octogenarians. T2D was newly diagnosed in 29 (10 men, 19 
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women) octogenarians, which represented 18.8% of the investi-
gated octogenarian population.
 According to Matthews’  [23] ‘homeostasis model assessment 
of insulin resistance’ (HOMA-IR) as an index for insulin resis-
tance was calculated by the formula: (fasting insulin [  U/ml]  ! 
fasting glucose [m M ])/22.5. 
 Laboratory Analyses 
 Plasma triglycerides, total cholesterol, HDL, and LDL choles-
terol were determined by standard methods on a modular ana-
lyzer (Roche, Indianapolis, Ind., USA), free fatty acids on a Cobas 
Mira analyzer (Global Medical Instrumentation, Inc., Ramsey, 
Minn., USA), and plasma glucose on a DX80 analyzer (Beckman-
Coulter, Fullerton, Calif., USA). HbA 1C was measured by fully 
automated HPLC system (Bio-Rad Laboratories, Richmond, Ca-
lif., USA). Plasma levels of insulin and C-peptide were determined 
by enzyme-linked immunosorbent assays (ELISA) from Bio-
Source (BioSource Europe SA, Belgium), and proinsulin by an 
ELISA from DRG Diagnostics (Marburg, Germany).
 Assay for Adiponectin Multimer Complexes 
 The measurement of adiponectin multimer complexes was 
performed using the Adiponectin (Multimeric) ELISA from 
 ALPCO Diagnostics (Salem, N.H., USA) for quantitative and se-
lective determinations of HMW, MMW, and total adiponectin in 
serum. This assay is able to directly quantify total adiponectin, 
HMW + MMW and HMW. Concentrations of LMW and MMW 
were obtained by subtracting HMW + MMW from total adipo-
nectin and HMW from HMW + MMW, respectively. The ELISA, 
which uses two monoclonal antibodies, had a linear range of 
0.075–4.8 ng/ml. Intra-assay coefficients of variations for total, 
HMW + MMW, and HMW adiponectin were reported to be 5.3, 
4.1 and 3.3%, respectively. The interassay coefficients of varia-
tions were 5.0, 6.0 and 5.7% for total, HMW + MMW, and HMW 
adiponectin, respectively. Each of the three forms of adiponectin 
multimer levels closely correlated with the total adiponectin levels 
in healthy subjects  [11] .
 Statistics 
 Differences of basal anthropometric and clinical data in men 
and women among multiple groups (octogenarians with NGT, 
with IGT or type 2 diabetes mellitus, and middle-aged (younger) 
individuals with NGT or type 2 diabetes mellitus) were analyzed 
by univariate analysis of variance (ANOVA) and post-hoc Bonfer-
roni tests. 
 To avoid significant pharmacological effects on study results, 
specific drug effects were excluded by a separate analysis of vari-
ance preceding subsequent statistical evaluation.
 Comparisons of serum levels of separate adiponectin isoforms 
among sex-stratified groups of octogenarians and controls were 
realized by a univariate model of variance with age and BMI as 
covariates (ANCOVA) and post-hoc testing with p values correct-
ed for multiple testing (Bonferroni procedure). Complex interac-
tion of adiponectin isoforms and all groups of investigation was 
analyzed using a model of multivariate analysis of variance with 
values adjusted for sex, age and BMI. Group differences were sub-
sequently tested by univariate analysis of variance with p values 
corrected for multiple testing (Bonferroni procedure). 
 Partial correlation tests were applied to evaluate the strength 
of association between total adiponectin and adiponectin iso-
forms with clinical data. The correlation has been controlled for 
BMI. Partial r and two-tailed significance have been indicated. 
 Data are given as mean with 95% confidence interval, unless 
otherwise stated. A value of p  ! 0.05 was considered statistically 
significant. All statistical analyses were performed with the SPSS 
statistical package (v16.0 for Windows; SPSS, Chicago, Ill., USA).
 Results 
 Basic Characteristics of the Study Population 
 Anthropometric data and baseline metabolic param-
eters of octogenarians and control subjects are given in 
 tables 1 (men) and  2 (women). Middle-aged individuals 
with T2D of both sexes displayed characteristic diabetes-
associated changes in comparison to middle-aged nor-
moglycemic controls, like higher values for BMI, systolic 
blood pressure, HbA 1c , HOMA-IR and plasma triglycer-
ides ( tables 1, 2 ). In contrast, these parameters were not 
significantly different between octogenarians with T2D 
and octogenarians with NGT of both sexes. These data 
led to the suggestion that although octogenarians with 
T2D fulfill the classification criteria for diabetes mellitus, 
based on fasting blood glucose and 2-hour postchallenge 
glucose level, they represent a specific pathogenetic enti-
ty. In order to proof this assumption, the time course of 
insulin, C-peptide, and proinsulin during OGTT have 
been analyzed. In octogenarian men with T2D, an at-
tenuated increase in insulin at 30 min OGTT indicated a 
delayed response to glucose challenge ( fig. 1 ). In contrast 
to middle-aged individuals with T2D, in whom maxi-
mum insulin level was observed 90 min after glucose 
load, the insulin level in octogenarians with T2D in-
creased until the end of the observation period ( fig. 1 ). In 
accordance,    comparable    kinetics   could   be   demonstrat-
ed for C-peptide curves (online suppl. table A, www.
karger.com/doi/10.1159/000316575). In middle-aged in-
dividuals with T2D, the level of proinsulin reached a 
maximum also at 90 min OGTT, which remained un-
changed up to 120 min (online suppl. table B). The abso-
lute values of proinsulin at 90 min in octogenarians with 
T2D tended to be lower, but increased further until 120 
min (online suppl. table B). Statistically significant differ-
ences of proinsulin/insulin ratios during OGTT between 
octogenarians and middle-aged controls with T2D could 
not be established (online suppl. table C).
 Taken together, these observations underline the spec-
ificity of the investigated octogenarian population. In 
particular, octogenarians with T2D do not reveal obvious 
characteristics of the metabolic syndrome or beta-cell in-
sufficiency. It is suggested that a combination of reduced 
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peripheral glucose consumption and moderately altered 
beta-cell function may result in a diabetic state, which is 
different from the situation in younger diabetic individu-
als with obesity and clustered metabolic deteriorations.
 Total Serum Adiponectin and Adiponectin Multimer 
Isoforms  
 Effect of Age 
 In comparison to the middle-aged normoglycemic 
male control group, serum concentrations of total adipo-
nectin and all adiponectin isoforms were higher in nor-
moglycemic octogenarian men ( table 3 ). In octogenarian 
men, the HMW/total adiponectin ratio was higher (41.7 
vs. 36.7%), the LMW/total adiponectin ratio lower (36.0 
vs. 39.1%) than in normoglycemic middle-aged men. 
Male octogenarians with T2D revealed significantly 
higher serum levels of total adiponectin, HMW adipo-
nectin, and MMW adiponectin than middle-aged men 
with T2D. LMW adiponectin was not different between 
these two groups.
 Similarly, serum concentrations of all adiponectin iso-
forms were higher in normoglycemic octogenarian wom-
en, with the exception of LMW adiponectin that did not 
reach significance ( table 3 ). Furthermore, the HMW/total 
adiponectin ratio was higher (47.5 vs. 43.1%), the LMW/
total adiponectin ratio was significantly lower in normo-
glycemic octogenarian women (27.8 vs. 36.7%, p = 0.014), 
when compared with normoglycemic middle-aged wom-
en. Like in men, female octogenarians with T2D had sig-
nificantly higher serum levels of total adiponectin, HMW 
adiponectin, and MMW adiponectin than middle-aged 
women with T2D ( table 3 ). 
Table 1.  Basal anthropometric and clinical data of male octogenarians with NGT (NGT-Oc), IGT (IGT-Oc), and 
type 2 diabetes mellitus (T2D-Oc), and of middle-aged (younger) male normoglycemic controls (NGT-Y) and 
individuals with type 2 diabetes (T2D-Y)
NGT-Oc 
(n = 24)
IGT-Oc 
(n = 24)
T2D-Oc 
(n = 10)
NGT-Y 
(n = 11)
T2D-Y 
(n = 14)
p
Age, years mean 83.0 83.0 82.7 43.3 55.5 <0.0011, 2
95% CI 82.1–84.0 82.2–83.8 81.2–84.3 37.2–49.4 50.9–60.1
BMI mean 26.4 24.0 26.9 25.2 29.4 <0.0013
95% CI 25.1–27.7 22.9–25.1 24.1–29.8 24.5–25.9 27.7–31.0
WHR mean 0.95 0.94 0.98 0.91 0.98 <0.0114
95% CI 0.93–0.98 0.92–0.96 0.93–1.03 0.87–0.94 0.96–1.01
RR syst., mm Hg mean 135 133 126 127 145 <0.0075
95% CI 129–141 128–138 116–137 116–139 136–155
RR diast., mm Hg mean 81 78 72 73 84 <0.014
95% CI 77–85 73–83 63–80 67–80 77–90
HbA1c, % mean 5.5 5.4 5.9 5.3 6.2 <0.0013
95% CI 5.4–5.7 5.2–5.6 5.5–6.2 5.0–5.6 5.9–6.5
HOMA-IR mean 2.5 3.3 3.1 2.0 5.3 <0.0012
95% CI 2.0–3.0 2.7–3.9 2.1–4.2 1.4–2.6 3.5–7.1
TG, mM mean 0.96 1.17 1.19 1.41 2.21 <0.0016
95% CI 0.86–1.06 1.01–1.32 0.78–1.60 1.08–1.75 1.19–3.22
Total chol., mM mean 4.30 4.29 4.47 5.32 5.03 <0.0117
95% CI 3.86–4.74 3.74–4.83 3.88–5.06 4.60–6.03 4.45–5.61
HDL-C, mM mean 1.31 1.30 1.28 1.57 1.21 <0.074
95% CI 1.15–1.48 1.01–1.58 1.09–1.48 1.36–1.78 1.09–1.34
LDL-C, mM mean 2.61 2.50 2.68 3.50 3.13 <0.0157
95% CI 2.23–2.98 2.13–2.87 2.07–3.29 2.89–4.10 2.62–3.63
FFA, mM mean 0.43 0.51 0.66 0.56 0.53 <0.173
95% CI 0.32–0.55 0.42–0.60 0.44–0.88 0.29–0.83 0.43–0.63
TG = Plasma triglycerides; FFA = free fatty acids. Group differences tested by univariate analysis of variance; 
Bonferroni test p ^ 0.05: 1 NGT-Y vs. all; 2 T2D-Y vs. all; 3 T2D-Y vs. NGT-Oc, IGT-Oc, NGT-Y; 4 T2D-Y vs. 
NGT-Y; 5 T2D-Y vs. NGT-Y, T2D-Oc; 6 T2D-Y vs. NGT-Oc, IGT-Oc, T2D-Oc; 7 NGT-Y vs. IGT-Oc.
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 Effect of Sex 
 Women of the octogenarian NGT group had signifi-
cantly higher total, HMW, and MMW adiponectin than 
men in the corresponding octogenarian NGT group. Se-
rum LMW adiponectin of both groups was not statisti-
cally different ( table 3 ). The same tendencies could also 
be detected in the group of middle-aged individuals with 
normoglycemia and in the octogenarian IGT group 
showing significantly higher levels in women of total, 
HMW, and LMW adiponectin, but no significant differ-
ences for MMW multimers. 
 Significantly higher serum concentrations of total and 
HMW adiponectin were found in middle-aged women 
with T2D in comparison to men of the same group. In 
contrast, no differences could be established between 
male and female octogenarians with T2D.
 Effect of T2D 
 Middle-aged men with T2D revealed a tendency of 
lower total, HMW, and MMW adiponectin, which did 
not reach statistical significance ( table 3 ). Unlike men, 
middle-aged women with T2D were characterized by a 
tendency for lower total and LMW adiponectin. This 
tendency was enhanced in female octogenarians with 
T2D, resulting in significantly lower LMW adiponectin. 
In addition, female octogenarians with T2D displayed 
also a tendency of lower HMW adiponectin. Taken to-
gether, these changes resulted in significantly lower to-
tal adiponectin in female octogenarians with T2D ( ta-
ble 3 ). 
 In accordance, significantly lower values for LMW ad-
iponectin could also be observed in male octogenarians 
with T2D in comparison with the normoglycemic octo-
genarian group ( table 3 ). In contrast to female octogenar-
ians, these changes were not accompanied by lower HMW 
Table 2.  Basal anthropometric and clinical data of female NGT-Oc, IGT-Oc, T2D-Oc, NGT-Y and T2D-Y
NGT-Oc
(n = 38)
IGT-Oc
(n = 39)
T2D-Oc
(n = 19)
NGT-Y
(n = 13)
T2D-Y
(n = 19)
p
Age, years mean 83.3 83.3 82.4 44.3 54.2 <0.0011, 2
95% CI 81.9–84.7 82.2–84.3 80.8–84.0 41.7–46.9 50.2–58.2
BMI mean 26.5 25.4 28.3 24.1 32.0 <0.0013
95% CI 25.0–27.9 23.8–26.9 25.5–31.0 22.9–25.3 28.3–35.7
WHR mean 0.91 0.91 0.90 0.85 0.92 <0.117
95% CI 0.88–0.93 0.89–0.94 0.86–0.93 0.78–0.91 0.89–0.95
RR syst., mm Hg mean 136 140 134 120 140 <0.0071
95% CI 132–141 134–146 126–142 109–131 131–149
RR diast., mm Hg mean 77 76 81 71 86 <0.0054
95% CI 73–80 72–80 76–86 62–80 80–92
HbA1c, % mean 5.6 5.4 6.0 5.3 6.2 <0.0013, 5
95% CI 5.3–5.9 5.3–5.5 5.7–6.3 5.1–5.4 6.0–6.5
HOMA-IR mean 3.0 3.0 3.8 2.2 6.2 <0.0012
95% CI 2.4–3.6 2.5–3.4 3.0–4.6 1.6–2.8 4.7–7.7
TG, mM mean 1.22 1.39 1.55 1.01 1.84 <0.0034
95% CI 1.12–1.33 1.21–1.58 1.23–1.88 0.74–1.29 1.29–2.39
Total chol., mM mean 5.29 5.35 5.02 5.12 5.24 <0.847
95% CI 4.99–5.58 5.00–5.71 4.57–5.47 4.64–5.60 4.84–5.64
HDL-C, mM mean 1.49 1.48 1.31 2.15 1.44 <0.0011
95% CI 1.37–1.61 1.35–1.62 1.18–1.44 1.91–2.40 1.24–1.63
LDL-C, mM mean 3.27 3.28 3.02 2.87 3.20 <0.599
95% CI 3.00–3.54 2.98–3.59 2.64–3.40 2.45–3.29 2.82–3.57
FFA, mM mean 0.61 0.67 0.67 0.54 0.79 <0.044
95% CI 0.53–0.69 0.59–0.76 0.55–0.79 0.43–0.66 0.67–0.91
Group differences tested by univariate analysis of variance; Bonferroni test p ̂  0.05: 1 NGT-Y vs. all; 2 T2D-
Y vs. all; 3 T2D-Y vs. NGT-Oc, IGT-Oc, NGT-Y; 4 T2D-Y vs. NGT-Y; 5 IGT-Oc vs. T2D-Oc.
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adiponectin. Therefore, no differences have been found 
for total adiponectin between male normoglycemic octo-
genarians and octogenarians with T2D.
 Based on the observation that LMW adiponectin was 
lower in male as well as in female octogenarians with 
T2D, a multivariate analysis was performed in a dataset 
stratified by sex with all observation groups (octogenar-
ians and middle-aged controls) and both sexes ( table 4 ). 
The data were adjusted for sex, age, and BMI by using 
these parameters as covariates. Generally, the resulting 
multivariate model indicated a significant effect of all ob-
servation groups on serum adiponectin levels (Lawley-
Hotellings’s trace: p = 0.047). The subsequent univariate 
multi-range analysis with p values corrected for multiple 
tests (Bonferroni procedure) confirmed significantly 
lower levels of LMW adiponectin in octogenarians with 
T2D in comparison to NGT octogenarians and octoge-
narians with IGT ( table 4 ).
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 Fig. 1. Time course of plasma glucose and insulin in male and female octogenarians with NGT (NGT-Oc), IGT 
(IGT-Oc), type 2 diabetes (T2D-Oc) and corresponding middle-aged (younger) control groups with NGT (NGT-
Y) and type 2 diabetes (T2D-Y) after standard OGTT.  *  p  ̂  0.05 vs. NGT-Y and NGT-Oc ;  #  p  ̂  0.05 vs. IGT-
Oc;  §  p  ̂  0.05 vs. NGT-Y;  +  p  ̂  0.05 vs. T2D-Oc. 
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 Serum concentrations of total adiponectin and all ad-
iponectin isoforms of male and female octogenarians 
with IGT were not statistically different from those of 
NGT octogenarians ( table 3 ). 
 Correlation Analyses of Adiponectin with Clinical 
Data in Octogenarians 
 The results of the partial correlation analyses with 
data controlled for BMI are shown in online supplemen-
tary table D. An exceptionally high direct correlation of 
total adiponectin and all adiponectin multimer complex-
es with HDL cholesterol was found in both men and 
women. On the other hand, hip circumference was in-
versely correlated with total, HMW, and MMW adipo-
nectin in men and women, and with LMW adiponectin 
in women only. Triglyceride levels revealed an inverse 
correlation with total, HMW, and MMW adiponectin 
and a direct correlation with the LMW/total adiponectin 
ratio in women.
 Interestingly, LMW adiponectin, in contrast to HMW 
and MMW adiponectin, revealed a strong inverse corre-
lation with fasting and 2-hour postchallenge glucose con-
centration in men and with 2-hour postchallenge glucose 
in women. Furthermore, the insulin levels 2 h after glu-
cose load were inversely correlated with all adiponectin 
multimer isoforms in women.
Table 3. Fasting serum levels of total adiponectin and adiponectin isoforms in NGT-Oc, IGT-Oc, T2D-Oc, NGT-Y and T2D-Y
Male octogenarians M ale younger controls 
NGT-Oc (n = 24) IGT-Oc (n = 24) T2D-Oc (n = 10) p NGT-Y ( n = 24) T2D-Y (n = 14) p
Total adiponectin 7.6 (6.3–8.8) 7.1 (5.8–8.4) 6.7 (4.8–8.7) 0.750 5.0 (3.4–6.6) 3.9 (2.5–5.2) 0.363
HMW adiponectin 3.3 (2.6–4.0) 3.1 (2.3–3.8) 3.3 (2.2–4.4) 0.898 2.0 (1.1–2.9) 1.4 (0.6–2.2) 0.390
MMW adiponectin 1.6 (1.3–2.0) 1.9 (1.5–2.2) 1.6 (1.1–2.2) 0.523 1.3 (0.9–1.7) 0.7 (0.4–1.1) 0.091
LMW adiponectin 2.7 (2.2–3.1) 2.1 (1.7–2.6) 1.8 (1.1–2.4) 0.0491 1.7 (1.2–2.3) 1.7 (1.3–2.2) 0.989
Female octogenarians Female younger controls
NGT-Oc (n = 38) IGT-Oc (n = 39) T2D-Oc (n = 19) p NGT-Y (n = 13) T2D-Y (n = 19) p
Total adiponectin 10.6 (9.3–11.9) 10.1 (8.9–11.4) 8.3 (6.5–10.1) 0.0401 7.1 (5.6–8.7) 5.8 (4.6–7.0) 0.258
HMW adiponectin 5.2 (4.4–6.0) 4.8 (4.0–5.6) 4.1 (2.9–5.2) 0.296 2.9 (2.0–3.9) 2.8 (2.0–3.5) 0.827
MMW adiponectin 2.5 (2.2–2.9) 2.2 (1.8–2.5) 2.2 (1.6–2.7) 0.283 1.5 (1.0–2.1) 1.1 (0.6–1.5) 0.277
LMW adiponectin 2.9 (2.5–3.2) 3.1 (2.8–3.5) 2.1 (1.5–2.6) 0.0141, 2 2.7 (2.1–3.2) 2.0 (1.5–2.4) 0.089
Dat a are presented as means [g/ml] with 95% confidence interval; differences analyzed by ANCOVA with data adjusted for age 
and BMI; Bonferroni test p ^ 0.05: 1 T2D-Oc vs. NGT-Oc; 2 T2D-Oc vs. IGT-Oc.
Table 4. Results of a multivariate analysis of variance of the whole study population with age, sex, and BMI as covariates (effect of 
groups in the multivariate model: p = 0.047 by Lawley-Hotelling’s trace)
G roups Univariate
analysis
Post-hoc analysis 
with Bonferroni 
correction
NGT-Oc
(n = 62)
IGT-Oc
(n = 63)
T2D- Oc
(n = 29)
NGT-Y
(n = 24)
T2D-Y
(n = 33)
p p
HMW adiponectin 3.9 (3.2–4.6) 3.7 (3.0–4.4) 3.3 (2.4–4.2) 3.9 (2.0–5.8) 3.5 (2.2–4.7) 0.626 n.s.
MMW adiponectin 1.9 (1.6–2.2) 1.8 (1.4–2.1) 1.7 (1.2–2.1) 2.2 (1.3–3.1) 1.7 (1.1–2.3) 0.402 n.s.
LMW adiponectin 2.6 (2.2–2.9) 2.6 (2.2–3.0) 1.8 (1.3–2.2) 2.7 (1.8–3.7) 2.3 (1.7–3.0) 0.002 0.0031
Dat a are presented as means [g/ml] with 95% confidence interval adjusted for age, sex and BMI; Bonferroni test: 1 T2D-Oc vs. 
NGT-Oc and IGT-Oc.
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 Discussion 
 Aging is associated with an increased risk of insulin 
resistance and diabetes mellitus. The current study on a 
clinically well-characterized population of octogenarians 
with different insulin sensitivity demonstrates selectively 
lower serum LMW adiponectin in male and female octo-
genarians with T2D. Serum levels of LMW adiponectin 
were reversely correlated with plasma glucose level 2 h 
after oral glucose challenge. A tendency of lower LMW 
adiponectin has also been found in a middle-aged group 
of female individuals with T2D, but not in a correspond-
ing middle-aged male group.
 Serum levels of total adiponectin and its isoforms are 
known to be affected by aging  [24, 25] , sex  [24–26] , and 
insulin sensitivity status  [24–26] . In accordance with ear-
lier studies describing increased total adiponectin with 
age  [24, 25] , the present study revealed higher levels of 
total adiponectin and adiponectin isoforms in normogly-
cemic octogenarians of both genders. The age-dependent 
increase in total adiponectin was slightly more pro-
nounced in men (77%) than in women (54%). While in 
men this increase was primarily due to the increase of 
HMW and LMW adiponectin, in women the increase of 
total adiponectin was mainly induced by the elevation of 
HMW and MMW adiponectin. As a result, the HMW/
total adiponectin ratio increased in normoglycemic octo-
genarian men from 36.7 to 41.7% and in women from 43.1 
to 47.5%, when compared with normoglycemic middle-
aged individuals. Concurrently, the LMW/total adipo-
nectin ratio decreased in normoglycemic octogenarian 
men from 39.1 to 31.1% and in women from 36.7 to 27.8% 
in comparison to middle-aged controls. 
 Although an increase in adiponectin levels with age 
has been reported by several studies  [24, 25] , the mecha-
nisms for an age-related adiponectin increase are not ful-
ly understood. The effect of aging has been partially at-
tributed to the reduction in the inhibitory effect of testos-
terone on adiponectin production with age. Notably, 
neither castration nor testosterone treatment modified 
the transcription activity of the adiponectin gene in adi-
pocytes, suggesting that the regulation occurs at a post-
transcriptional level  [26] . Recent studies have demon-
strated that the secretion of HMW adiponectin from ad-
ipocytes is much slower than that of LMW and MMW 
oligomer complexes, and that testosterone treatment 
leads to a further decrease in HMW adiponectin secre-
tion  [27] . These data suggest that different oligomeric 
complexes of adiponectin are released from adipocytes 
through at least two distinct secretory pathways  [27] . 
Based on this, testosterone may selectively interfere with 
the HMW-specific mechanism of adiponectin secretion 
from the adipocyte. In line with this hypothesis, a more 
pronounced increase in HMW adiponectin in normogly-
cemic octogenarians could be explained in part by a se-
lectively reduced inhibition of the testosterone-sensitive 
HMW secretory pathway. Very recently, an effect of fe-
male sex steroids on adiponectin oligomeric distribution 
in women has also been described  [28] . While total, 
HMW, and MMW adiponectin was negatively associated 
with estradiol and progesterone, no association was ob-
served for LMW adiponectin  [28] . It is noteworthy that 
increasing concentrations of testosterone or estradiol in-
fluenced neither mRNA or protein expression nor adipo-
nectin oligomer secretion in cultured preadipocytes  [29] . 
 Based on a differential hormonal background, sexual 
dimorphism in total, HMW, and MMW adiponectin has 
been reported in several studies on younger individuals  [10, 
11] . In extension of these data, the present study demon-
strated gender differences also in octogenarians, in whom 
the hormonal background is expected to be more balanced. 
Women revealed significantly higher values for total, 
HMW, MMW, but not for LMW adiponectin. This obser-
vation is in accordance with Ebinuma et al.  [11] who de-
scribed the lack of gender difference for LMW adiponectin 
in a younger population, thereby supporting the hypothe-
sis that, in contrast to higher molecular multimer complex-
es, sexual hormones might be less involved in the regula-
tion of LMW adiponectin biosynthesis and secretion. 
 A growing number of studies indicate that the oligo-
mer distribution of adiponectin is of greater relevance for 
its insulin-sensitizing activity than the plasma adiponec-
tin concentration in total  [7, 9, 30] . Earlier studies empha-
sized the importance of HMW adiponectin for the predic-
tion and modulation of insulin resistance  [12, 14] . The re-
duction in insulin sensitivity in patients with T2D was 
accompanied by a decline in HMW adiponectin account-
ing for the total adiponectin reduction  [31] . Moreover, re-
cent data demonstrated that the HMW/total adiponectin 
ratio was independent of total adiponectin related to the 
risk of T2D  [14, 32] and coronary artery disease  [10, 33] . 
Although the insulin-sensitizing properties of adiponec-
tin have been mainly attributed to HMW adiponectin and 
the HMW/total adiponectin ratio  [30] , Fruebis et al.  [6] 
demonstrated that different oligomers of adiponectin ac-
tivated different signaling pathways in myotubes and iso-
lated rat muscles. LMW adiponectin, but not the HMW 
isoform, induced phosphorylation of the AMPK  subunit 
and thereby its activation in myotubes and isolated rat 
muscles. In addition, the trimeric globular head of adipo-
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nectin showed a much higher binding affinity than full-
length adiponectin to Adipor1, the predominant form of 
adiponectin receptor expressed in skeletal muscle  [34] . On 
the basis of these findings, it was supposed that the trimer 
is the most potent isoform mediating beneficial metabol-
ic effects of adiponectin in skeletal muscle. 
 Interestingly, the present study demonstrated signifi-
cantly lower serum LMW adiponectin in male and female 
octogenarians with T2D compared to normoglycemic oc-
togenarians. In men with T2D, this situation resulted 
from a lack of age-induced LMW adiponectin increase, 
which was characteristic of normoglycemic men. In wom-
en, already middle-aged individuals with T2D exhibited a 
strong tendency for lower LMW adiponectin. This ten-
dency was enhanced in octogenarian women with T2D. 
The pathogenetic mechanisms behind these changes are 
unknown. An interaction between hormonal shifts and 
the development of insulin resistance should be taken into 
consideration. One important point to consider is the spe-
cific metabolic situation of the investigated population of 
octogenarians. Clearly categorized by OGTT in terms of 
blood glucose and corresponding insulin curves, male and 
female octogenarians with T2D did not differ from octo-
genarians with NGT in BMI, WHR, blood pressure, HDL 
and total cholesterol. In accordance with earlier publica-
tions  [35–38] , the data of the present study revealed a high-
ly significant direct correlation of all adiponectin multi-
mer isoforms with HDL cholesterol in men as well as in 
women. Therefore, it was not surprising that the missing 
difference in HDL cholesterol between T2D octogenari-
ans and the corresponding NGT group was accompanied 
by an absence of significant differences in HMW and 
MMW adiponectin. The nature of the close association 
between adiponectin and HDL cholesterol is not fully un-
derstood. However, in a rat model an increase in HDL cho-
lesterol and a decrease in triglycerides were induced 
through the permanent activation of the AMPK pathway 
by an adenosine analogue  [39] . This points, at least in part, 
to a direct effect of adiponectin on HDL metabolism.
 The contribution of a selective decline in LMW adipo-
nectin in octogenarians with T2D to the pathophysiology 
of diabetes has not been completely elucidated. Besides its 
peripheral action, adiponectin plays a significant role in 
the central regulation of food intake and energy expendi-
ture. Very recently, Coope et al.  [18] demonstrated in rats 
that intracerebroventricular infusion of adiponectin in-
duced an anorexigenic effect that was mediated through 
hypothalamic AdipoR1 receptors. Notably, in both hu-
mans and rodents, only the trimeric and hexameric com-
plexes of adiponectin are present in cerebrospinal fluid 
 [20, 21] . The HMW oligomeric adiponectin is virtually 
undetectable in cerebrospinal fluid, perhaps due to the 
extremely large size of this complex ( 1 500 kDa), which 
makes it difficult to translocate across the blood-brain 
barrier. Thus, the reduction in LMW adiponectin may be 
involved in a decline in insulin sensitivity in skeletal 
muscle and the central disinhibition of food intake pro-
moting insulin resistance and obesity.
 The increase in plasma adiponectin with age in normo-
glycemic individuals raised the question whether adipo-
nectin might be a marker for longevity. This idea has been 
supported by recent studies showing an association of 
lower adiponectin levels with early onset and severity of 
coronary artery disease  [40–42] . Low plasma levels of ad-
iponectin were independently associated with increased 
intraventricular septum thickness, posterior ventricular 
wall thickness, and left ventricular mass index  [43] . At the 
same time, evidence accumulates that increased adipo-
nectin levels were closely associated with not only all-
cause mortality but also coronary heart disease (CHD) 
mortality in either sex  [44–46] . This association seems to 
be particularly strong in the elderly and in patients at high 
risk for CHD. A prospective study on more than 4,000 el-
derly men aged 60–79 confirmed the results of previous 
studies showing that high adiponectin levels were associ-
ated with significantly increased mortality in elderly pa-
tients with CHD  [46] . Despite the rapidly accumulating 
literature, it is still uncertain whether adiponectin levels 
have any clinical significance for risk stratification in car-
diovascular disease and aging or whether they just reflect 
the activation of complex and opposing underlying mech-
anisms. Therefore, the role of adiponectin as a marker for 
longevity should be discussed with caution.
 In conclusion, the present study demonstrates signifi-
cantly lower levels of plasma LMW adiponectin in male 
and female octogenarians with T2D in comparison to oc-
togenarians with NGT, probably as a result of the interac-
tion of aging and insulin resistance. At the same time, 
serum levels of HMW and MMW adiponectin isoforms 
were not significantly different. The pathophysiological 
importance of reduced serum LMW adiponectin in indi-
viduals with higher age and increased insulin resistance 
remains to be established.
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